

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME MAULDIN, Patrick D. (PhD)	POSITION TITLE Research Health Scientist (VAMC) and Associate Professor of Pharmacy & Clinical Sciences (MUSC)		
e-RA COMMONS USER NAME MAULDINP			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Univ. of South Carolina, Columbia, SC	B.S.	1985	Economics
Syracuse University, Syracuse, NY	M.A.	1987	Economics
Emory University, Atlanta, GA	Ph.D.	1993	Economics

A. Positions and Honors.

Positions and Employment:

- 1993-1996 Assistant Professor, Div. Health Policy & Management, Emory School Public Health, Atlanta, GA
- 1994-1996 Assistant Professor, and Assoc. Dir. Program in Health Care Epi. and Decision Making Research, Emory University Center for Clinical Evaluation Sciences, Emory School of Medicine, Atlanta, GA
- 1996-1997 Assistant Professor, Dept. Biometry & Epidemiology, MUSC, Charleston, SC
- 1997-Present Associate Professor (Joint Appt.), Dept Biometry and Epidem., MUSC, Charleston, SC
- 2003-Present Associate Professor, Dept Pharmacy & Clinical Sciences, MUSC, Charleston, SC
- 2005-Present Research Health Scientist/Principal Investigator (5/8th VA), HSR&D Targeted Research Enhancement Program, Research Service, VAMC, Charleston, SC

Other Experience and Professional Memberships:

- 1992-1995 Health Economist, CDC, Div of Cancer Prevention & Control, Atlanta, GA (IPA with CDC)
- 1997-2003 Executive Director, The Clinical Innovation Group, MUSC Foundation for Research & Development, Medical University of South Carolina, Charleston, SC
- 2007 NIH/NINDS (ZNS1 SRB-G) Special Emphasis Panel Reviewer.
- 2006-Present Scientific Merit Review Board, Veterans Affairs HSR&D, Washington, DC

B. Selected peer-reviewed publications (in chronological order)

1. **Mauldin PD.** "A note on errors-in-variables in panel data," Biometrical J 1992; 34(8): 1013-1015.
2. **Mauldin PD,** and WS Weintraub. "Determining patient utility following coronary revascularization," J Invasive Cardio 1993; 5(5): 171-178.
3. **Mauldin PD,** et al. "Hospital resource utilization during CABG" J Intervent Cardio 1994;7(3): 379-384.
4. **Mauldin PD,** Jeong J, Becker ER, and WS Weintraub. "Provider cost and coronary revascularization: an econometric approach" Econometrics of Health Care Evaluation 1994; VII: 87-98.
5. Weintraub WS, **Mauldin PD,** and ER Becker. "An introduction to clinical microeconomic analysis: purposes and analytic methods," J Intervent Cardio 1994; 7(2): 281-289.
6. King SB, for EAST Investigators (**Mauldin PD**-EAST Investigator) "Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass Surgery: The Emory Angioplasty Surgery Trial (EAST)" NEJM 1994;331(16):1044-50.
7. **Mauldin PD,** Weintraub WS, ER Becker "Predicting hospital costs for first-time coronary artery bypass grafting from pre-operative and post-operative variables." Am J Cardio 1994; 74: 772-775.
8. Talley JD, **Mauldin PD,** and ER Becker. "An prospective randomized trial comparing 6 & 8 French guiding catheters in elective PTCA: technical, clinical and economic endpoints." J Intervent Cardio 1995;8(4):345-354.
9. Weintraub WS, **Mauldin PD,** Becker ER, Kosinski AS, and SB King III. "A comparison of the costs of and quality of life after coronary angioplasty and coronary surgery: results from the Emory Angioplasty vs Surgery Trial (EAST)." Circulation 1995; 92: 2381-2840.
10. Talley JD, **Mauldin PD,** and ER Becker. "A prospective randomized trial of 0.010-in. vs. 0.014-in. balloon PTCA systems, and interventional fellow vs. attending physician as primary operator in elective PTCA: economic, technical, and clinical endpoints." J of Intervent Cardio 1995; 8(6): 623-632.
11. Weintraub WS, Benard J, **Mauldin PD,** et al. "Declining resource utilization in interventional cardiology." Am J of Managed Care 1995; 1(1): 45-50.

12. Talley JD, and **PD Mauldin**. "The systems, the operators, the patients: analysis of the cost impact of PTCA equipment on health care," *J Intervent Cardio*, 8(4), 1995, 343-344.
13. Talley JD, **Mauldin PD**, and J Kupersmith. "Economic and angiographic factors in determining optimal catheter size in performing outpatient left sided heart and coronary angiography." *Am J Cardio* 1996;77: 374-378.
14. Becker ER, **Mauldin PD**, and ME Bernardino. "Using physician work RVUs to profile surgical packages: Methods and results for kidney transplant surgery." *Best Practices and Benchmarking* 1996; 1(3): 140-146.
15. Weintraub WS, **Mauldin PD**, et al. "Determinants of hospital charges and costs in acute myocardial infarction:a report from the Myocardial Infarction Cost Study (MICS) group." *Am J Managed Care* 1996;2:977-986.
16. Weintraub WS, Waksman R, Benard J, Hicks F, Canup D, Becker ER, **Mauldin PD**, and SB King III. "The influence of new devices on the costs of interventional procedures." *Am J Manage Care* 1996;2:1199-1208.
17. Talley JD, **Mauldin PD**, et al. "Costs, benefits, and therapeutic modifications associated with intracoronary ultrasound plus percutaneous transluminal coronary angioplasty (PTCA), versus PTCA alone." *Am J Cardio* 1996;77:1278-1282.
18. Mauldin JG, **Mauldin PD**, Feng TI, Adams EK, and VL Durkalski. "Determining the clinical efficacy and cost savings of external cephalic version." *Am J of Obstetrics and Gynecology* 1996; 175(6): 1639-1644.
19. JeongJ,and **PD Mauldin**"Estimating the weighting component of a health quality index"*Biometrical J* 1996;38:779-90.
20. Weintraub WS, Warner CD, **Mauldin PD**, Becker ER, Gomes D, Cook J, Kosinski A, and S Boccuzzi. "Economic winners and losers after introduction of an effective new therapy depends on the type of payment system." *Am J Managed Care* 1997; 3: 743-749.
21. TalleyJD, &**PDMauldin**."Publications concerning costs of various cardiovasc. procedures and drugs,"*AmJCardio* 1997;79:3-5.
22. Lee JS, Bailey MJ, Jeong J, **Mauldin PD**, and WS Weintraub. "A study on the cost-effectiveness of coronary revascularization: Introducing the Simultaneous MIMIC Health Status Model." *Health Economics*1997;6:613-23.
23. Tarnasky P, Palesch YY, Cunningham JT, **Mauldin PD**, et al."Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients w/sphincter of Oddi dysfunction." *Gastroenterology*1998;115:1518-1524.
24. Mauldin JG, Newman RB, and **PD Mauldin**. "Cost effective delivery management of the vertex/non vertex twin gestation." *Am J of Obstetrics and Gynecology* 1998; 179(4):864-869.
25. **Mauldin PD**, Jeong J, Weintraub WS, and ER Becker "A Multiple Outcome Model to Assess Cost-Effectiveness: Results from the Emory Angioplasty vs.Surgery Trial (EAST)" *Biometrical J*,1999;41(1):3-23.
26. Sahai A, **Mauldin PD**, et al. "Bile duct stones and laparoscopic cholecystectomy: A decision analysis to assess the roles of intra-operative cholangiography, EUS, and ERCP. " *Gastrointestinal Endoscopy*, 1999; 49:334-343.
27. Becker ER, Morris DC, Culler SD, **Mauldin PD**, et al., "The Changing Healthcare Market and How It Has Influenced the Treatment of Cardiovascular Disease - Part 1," *Am J Managed Care*,1999;5(9):1119-24.
28. Becker, ER, Morris DC, Culler SD, **Mauldin PD**, Shaw LJ, Talley JD, and WS Weintraub, "The Changing Healthcare Market: Outlook for the Future of Cardiovascular Disease - Part 2," *Am J of Managed Care*, 1999; 5(9): 1125-1132.
29. Adams EK, **Mauldin PD**, Mauldin JG, et al."Determining cost savings from attempted cephalic version in an inner city delivering population." *Health Care Management Science*,2000,3(3):185 192.
30. Becker ER, **Mauldin PD**, Weintraub WS and SB King. "Applying the Resource-Based Relative Value Scale to the Emory Angioplasty vs Surgery Trial." *Am J of Cardio*, 2000; 85(6): 685-691.
31. Weintraub WS, Becker ER, **Mauldin PD**, et al. "Costs of revascularization over eight years in the randomized and eligible patients in the EAST trial." *Am J of Cardio*, 2000; 86(7):747-752.
32. Hebert R, Palesch Y, Aabakken L, Hennessey W, **Mauldin PD**, and PB Cotton. "DDQ-15: a health-related quality of life instrument for patients with digestive disorders: self-administration by paper versus computer" *Health Services and Outcomes Research Methodology*, 2001; 2: 137-156.
33. Cotton, PB, Durkalski VL, Pineau BC, Palesch YY, **Mauldin PD**, et al. "Virtual colonoscopy (CT colonography. A multicenter comparison with standard colonoscopy for detection of mass lesions." *JAMA*, 2004; 291(14): 1713-1719.

34. Gillanders WE, Mikhitarian K, Hebert R, **Mauldin PD**, Palesch YY, et al. "Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: An interim analysis of a prospective multi-institutional cohort study." *Annals of Surgery*, 2004; 239(6): 828-840.
35. Jeong J, Becker ER, **Mauldin PD**, and WS Weintraub. "A Comparison of Self-Selectivity Corrections in Economic Evaluations and Outcomes Research." *Value in Health* 2005; 8(6): 656-666.
36. Mikhitarian K, Martin R, Mitas M, **Mauldin PD**, et al. "Molecular analysis improves the sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study." *Surgery*, 2005; 138(3):474-81.
37. Chumney E, **Mauldin PD**, and K Simpson. "Charges for Hospital Admissions Attributable to Health Disparities for African American Patients in South Carolina During 1998-2002" *J National Med Association*, 2006; 98(5):690-694.
38. Bosso JA, **PD Mauldin**. "Assessment of Effects of Fluoroquinolone Formulary Changes on Gram-negative Susceptibility and MRSA isolation rates Using Interrupted Time Series Analysis." *Antimicrobial Agents and Chemotherapy*, 2006; 50(6):2106-2112.
39. Bosso JA, **Mauldin PD**, LL Steed. "Consequences of Combining Cystic Fibrosis and non-Cystic Fibrosis derived *Pseudomonas aeruginosa* Antibiotic Susceptibility Results in Hospital Antibigrams." *Annals of Pharmacotherapy*, 2006; November 40: 1946-9.
40. Schnelldorfer T, **Mauldin PD**, Lewin DN, Adams DB. "Distal pancreatectomy for chronic pancreatitis: risk factors for postoperative pancreatic fistula." *J Gastrointest Surg* 2007;11:991-997.
41. **Mauldin PD**, Simpson KN, Palesch YY, et al. "Design of the Economic Evaluation for the Interventional Management of Stroke (III) Trial." *International J Stroke* 2008; 3(2): 138-144.
42. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin R, **Mauldin PD**, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, and JP Broderick for the IMS III Investigators. "Methodology of the Interventional Management of Stroke (IMS) III Trial." *International J Stroke* 2008; 3(2): 130-137.
43. **Mauldin PD**, Salgado CD, Durkalski VL, and JA Bosso. "Nosocomial infections due to Methicillin-resistant *S. aureus* and Vancomycin-resistant *Enterococcus*: Relationships with antibiotic use and cost drivers." *Annals of Pharmacotherapy* 2008; 42: 317-326.
44. Nietert PJ, Tilley BC, Zhao W, Edwards PF, Wessell AM, **Mauldin PD**, Polk PP (2008). "Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial." In press, *Medical Care*.
45. **Mauldin PD**, Guimaraes P, et al. "Optimal Frequency for Measuring Healthcare Utilization in Parkinson's Disease Using Participant Recall: The FS-TOO Resource Utilization Substudy." *Clinical Therapeutics* 2008;30:1553-1557.
46. Salgado CD, **Mauldin PD**, Fogle PJ, and JA Bosso. "Analysis of an Outbreak of *Clostridium difficile* Infection Controlled with Enhanced Infection Control Measures." In press, *American J Infection Control*.

C. Research Support (Federal)

IIR 06-219-2 Mauldin (PI)
VA HSR&D

03/01/2008–02/29/2010

Ethnic Differences in Medication Adherence & Cost for Elderly Veterans with Type-II Diabetes Mellitus

The goals of this project are to characterize medication non-adherence (MNA) across racial/ethnic groups of elderly (age ≥ 65) diabetic veterans, to determine the longitudinal effect of MNA on health care costs to the VA and Medicare (federal payer) and mortality across racial/ethnic groups, and to determine whether racial/ethnic variations in MNA explain racial/ethnic disparities in health care cost & mortality among elderly vets w/diabetes.

U01 NS052220 Palesch (PI)
NIH/NINDS

09/15/2005–05/31/2010

Interventional Management of Stroke Study

This is a randomized, open-label, multicenter study to assess IV rt-PA vs. IV/IA therapy for acute ischemic stroke. Dr. Mauldin receives no research funding in direct support of his own independent research for his involvement in this project.

Role: Co-Inv

IIR-04-421 Egede (PI)
VA HSR&D

08/01/2006–07/31/2010

Telepsychology Service Delivery for Depressed Elderly Veterans

To evaluate the effectiveness of in-home telepsychology intervention to deliver Behavioral Activation therapy to depressed elderly veterans. Dr. Mauldin receives no research funding in direct support of his own independent research for his involvement in this project.

Role: Co-Inv

R01 DK074739-01 Cotton (PI)
NIH/NIDDK

08/01/2007–07/31/2012

Evaluating Predictor Interventions in Sphincter of Oddi Dysfunction (EPISOD)

The overall goal of this application is to assess the value of endoscopic sphincterotomy as a potential treatment for adults diagnosed with type III Sphincter of Oddi dysfunction (SOD III). Dr. Mauldin receives no research funding in direct support of his own independent research for his involvement in this project.

Role: Co-Inv

PT073980 Acierno (PI)
Dept of Defense (USAMRAA)

01/08/2008–03/31/2012

Innovative Service Delivery for Secondary Prevention of PTSD in At Risk OIF-OEF Servicemen & Women

To develop and evaluate a secondary preventive intervention for PTSD in terms of its utility via telepsychology vs. in person treatment mediums. Dr. Mauldin receives no funding in direct support of his own independent research for his involvement in this project.

Role: Co-Inv

NIH 5 U01 NS43127 Tilley (PI)

08/01/2003–01/31/2008

FS-TOO Parkinson's Disease Statistical Center

This project is a futility study of two compounds to slow the disease progression in early untreated Parkinson's Disease.

Role: Co-Inv

Completed Research Support (Federal)

VISN 7 Research Career Development Role- PI
VA HSR&D

04/01/2005–03/31/2007

Racial Differences in Outcomes and Costs for VA Cancer Patients

The goal of this project was to provide funding for Dr. Mauldin to focus his research efforts on HSR within the VA, and specifically develop a Merit proposal to create an economic model that will explore differences between races on survival and costs of select chronic diseases, particularly cancer.

P01 HS10871 Role: Co-Inv, PI-Tilley
AHRQ

09/21/2000–08/31/2006

Understanding & Eliminating Health Disparities in Blacks: Biostatistics Core

The goal of this project is to move beyond the identification and description of African American/Caucasian health-related disparities to understanding the source within the African American population and identifying solutions designed to address these health issues.

R03 DK069328-01 Role: Co-Inv, PI-Cotton
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)

09/31/2004–01/31/2006

Planning Grant for SOD III Multicenter Trial

The major goal is to plan a Phase III multicenter trial in patients with suspected Sphincter of Oddi dysfunction (SOD) Type III.